12 results
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
and evaluated in a Phase 1 healthy volunteer study in 2020. The Phase 1 study was a randomized, double-blind, placebo-controlled dose escalation study … as hematological parameters, lipids, and creatine phosphokinase (CPK) (see graphs below). GLPG3667 is a potent, selective TYK2 inhibitor HV: healthy volunteer
6-K
EX-99.1
GLPG
Galapagos NV
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
compounds with improved pharmacology and selectivity profiles, and plan to select a preclinical candidate to move into a healthy volunteer study
6-K
EX-99.2
GLPG
Galapagos NV
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
evidence of the potential dual mode of action of SIK2/3. We plan to bring an SIK2/3 molecule with optimized pharmacology into a healthy volunteer
6-K
EX-99.2
ojfbvy4tn
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.1
1rgz3atl
27 Oct 20
Current report (foreign)
12:13pm
424B5
xza9pqemx 82k
18 Apr 17
Prospectus supplement for primary offering
12:00am
424B5
m0tb taowz4i
17 Apr 17
Prospectus supplement for primary offering
12:00am
- Prev
- 1
- Next